Infraslow closed-loop brain training for anxiety and depression (ISAD): a protocol for a randomized, double-blind, sham-controlled pilot trial in adult females with internalizing disorders

• Published in: Current controlled trials in cardiovascular medicine Vol. 23; no. 1; pp. 949 - 26
• Main Authors: Perez, Tyson M, Glue, Paul, Adhia, Divya B, Navid, Muhammad S, Zeng, Jiaxu, Dillingham, Peter, Smith, Mark, Niazi, Imran K, Young, Calvin K, De Ridder, Dirk
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 17.11.2022; BioMed Central; BMC
• Subjects: Adult; Anxiety; Anxiety Disorders; Bayes Theorem; Biofeedback training; Brain - physiology; Brain research; Care and treatment; Depression; Depressive Disorder, Major; Diagnosis; Double-blind studies; EEG neurofeedback; Electroencephalography; Female; Females; Generalized anxiety disorder; Humans; Infraslow fluctuations; Internalizing disorders; Major depressive disorder; Mental depression; Mental disorders; Mental illness; Methods; Neurobiology; Neurophysiology; Pilot Projects; Post traumatic stress disorder; Psychopathology; Psychotherapy; Randomized Controlled Trials as Topic; Social anxiety disorder; Study Protocol; Testing; New Zealand; Triple network; Default mode network; Salience network; Generalized anxiety disorder; Internalizing disorders; Infraslow fluctuations; Social anxiety disorder; Central executive network; EEG neurofeedback; Randomized controlled trial; Major depressive disorder
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-022-06863-z

The core intrinsic connectivity networks (core-ICNs), encompassing the default-mode network (DMN), salience network (SN) and central executive network (CEN), have been shown to be dysfunctional in individuals with internalizing disorders (IDs, e.g. major depressive disorder, MDD; generalized anxiety disorder, GAD; social anxiety disorder, SOC). As such, source-localized, closed-loop brain training of electrophysiological signals, also known as standardized low-resolution electromagnetic tomography (sLORETA) neurofeedback (NFB), targeting key cortical nodes within these networks has the potential to reduce symptoms associated with IDs and restore normal core ICN function. We intend to conduct a randomized, double-blind (participant and assessor), sham-controlled, parallel-group (3-arm) trial of sLORETA infraslow (<0.1 Hz) fluctuation neurofeedback (sLORETA ISF-NFB) 3 times per week over 4 weeks in participants (n=60) with IDs. Our primary objectives will be to examine patient-reported outcomes (PROs) and neurophysiological measures to (1) compare the potential effects of sham ISF-NFB to either genuine 1-region ISF-NFB or genuine 2-region ISF-NFB, and (2) assess for potential associations between changes in PRO scores and modifications of electroencephalographic (EEG) activity/connectivity within/between the trained regions of interest (ROIs). As part of an exploratory analysis, we will investigate the effects of additional training sessions and the potential for the potentiation of the effects over time. We will randomly assign participants who meet the criteria for MDD, GAD, and/or SOC per the MINI (Mini International Neuropsychiatric Interview for DSM-5) to one of three groups: (1) 12 sessions of posterior cingulate cortex (PCC) ISF-NFB up-training (n=15), (2) 12 sessions of concurrent PCC ISF up-training and dorsal anterior cingulate cortex (dACC) ISF-NFB down-training (n=15), or (3) 6 sessions of yoked-sham training followed by 6 sessions genuine ISF-NFB (n=30). Transdiagnostic PROs (Hospital Anxiety and Depression Scale, HADS; Inventory of Depression and Anxiety Symptoms - Second Version, IDAS-II; Multidimensional Emotional Disorder Inventory, MEDI; Intolerance of Uncertainty Scale - Short Form, IUS-12; Repetitive Thinking Questionnaire, RTQ-10) as well as resting-state neurophysiological measures (full-band EEG and ECG) will be collected from all subjects during two baseline sessions (approximately 1 week apart) then at post 6 sessions, post 12 sessions, and follow-up (1 month later). We will employ Bayesian methods in R and advanced source-localisation software (i.e. exact low-resolution brain electromagnetic tomography; eLORETA) in our analysis. This protocol will outline the rationale and research methodology for a clinical pilot trial of sLORETA ISF-NFB targeting key nodes within the core-ICNs in a female ID population with the primary aims being to assess its potential efficacy via transdiagnostic PROs and relevant neurophysiological measures. Our study was prospectively registered with the Australia New Zealand Clinical Trials Registry (ANZCTR; Trial ID: ACTRN12619001428156). Registered on October 15, 2019.